Attention Deficit Hyperactivity Disorder (ADHD)-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- GlobalData, the industry analysis specialist's new report, "Attention Deficit Hyperactivity Disorder ¨C Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the dynamism in the global ADHD market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ADHD sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global ADHD market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include triple reuptake inhibitors, GABA receptor modulators, acetylcholine receptor agonists, AMPA receptor modulators, serotonin receptor targettors, selective histamine antagonists, norepinephrine reuptake inhibitors and alpha-2 adrenergic agonists
-Analysis of the current and future market competition in the global ADHD market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
-Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the ADHD therapeutics market in the long run. Key future market players covered are Addrenex, Abbott Laboratories, Psychogenics, AstraZeneca and Cortex.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ADHD.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global ADHD market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global ADHD market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Attention Deficit Hyperactivity Disorder Market: Market Characterization
2.1 Overview
2.2 Attention Deficit Hyperactivity Disorder Market Size
2.3 Attention Deficit Hyperactivity Disorder Market Forecast and CAGR
2.4 Drivers and Barriers for Attention Deficit Hyperactivity Disorder Market
2.4.1 Drivers for Attention Deficit Hyperactivity Disorder Market
2.4.2 Barriers for Attention Deficit Hyperactivity Disorder Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Attention-Deficit Hyperactivity Disorder Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in ADHD Market
3.3.1 Daytrana (methylphenidate)
3.3.2 Vyvanse (lisdexamfetamine dimesylate, NRP-104, S-489)
3.3.3 Strattera (atomoxetine Hcl)
3.3.4 Intuniv (guanfacine hydrochloride, SPD 503, GXR)
3.3.5 Concerta (methylphenidate Hcl)
3.4 Key Takeaway
4 Attention Deficit Hyperactivity Disorder Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework  
4.3 Attention-Deficit Hyperactivity Disorder Therapeutics-Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Clonicel
4.4.2 ABT-089 (Pozanicline)
4.4.3 ABT-894 (Sofinicline)
4.4.4 Eltoprazine
4.4.5 AZD3480 (TC-1734) (Isopronicline)
4.5 Attention Deficit Hyperactivity Disorder Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.6 Attention Deficit Hyperactivity Disorder Pipeline-Pipeline by Clinical Phases of Development
4.6.1 Attention Deficit Hyperactivity Disorder Therapeutics-Phase III Clinical Pipeline
4.6.2 Attention Deficit Hyperactivity Disorder Therapeutics-Phase II Clinical Pipeline
4.6.3 Attention Deficit Hyperactivity Disorder Therapeutics-Phase I Clinical Pipeline
4.6.4 Attention Deficit Hyperactivity Disorder Therapeutics-Preclinical Pipeline
4.6.5 Attention Deficit Hyperactivity Disorder Therapeutics-Discovery Pipeline
4.7 Discontinued/Suspended Drugs for Attention Deficit Hyperactivity Disorder
4.8 Key Takeaway
5 Attention-Deficit Hyperactivity Disorder Market: Implications for Future Market Competition
6 Attention Deficit Hyperactivity Disorder Market: Future Players in ADHD Market
6.1 Introduction
6.2 Addrenex Pharmaceuticals
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Attention Deficit Hyperactivity Disorder Portfolio
6.3 Abbott Laboratories
6.3.1 Overview
6.3.2 CNS Portfolio
6.3.3 Attention Deficit Hyperactivity Disorder Product Portfolio
6.4 Psychogenics Inc
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Attention Deficit Hyperactivity Disorder Product Portfolio
6.5 Cortex Pharmaceuticals
6.5.1 Overview
6.5.2 CNS Portfolio
6.5.3 Attention Deficit Hyperactivity Disorder Product Portfolio
6.6 AstraZeneca
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Attention Deficit Hyperactivity Disorder Product Portfolio
7 Attention Deficit Hyperactivity Disorder Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
1.1 List of Tables
Table 1: Global ADHD Therapeutics Market, Revenue Forecasts, 2000-2007
Table 2: Global ADHD Therapeutics Market, Revenue Forecasts, 2008-15
Table 3: Major marketed products comparison in ADHD Market, 2009
Table 4: Attention-Deficit Hyperactivity Disorder Therapeutics-Most Promising Drugs Under Clinical Development, 2009
Table 5: Attention Deficit Hyperactivity Disorder Therapeutics-Phase III Clinical Pipeline, 2009
Table 6: Attention Deficit Hyperactivity Disorder Therapeutics-Phase II Clinical Pipeline, 2009
Table 7: Attention Deficit Hyperactivity Disorder Therapeutics-Phase I Clinical Pipeline, 2009
Table 8: Attention Deficit Hyperactivity Disorder Therapeutics-Preclinical Clinical Pipeline, 2009
Table 9: Attention Deficit Hyperactivity Disorder Therapeutics-Discovery Clinical Pipeline, 2009
......

List of Figures
1.2 List of Figures
Figure 1: Global ADHD Market Forecast, 2000-2015
Figure 2: Opportunity and Unmet Need, 2009
Figure 3: Strategic Competitor Assessment, 2009
Figure 4: Technology Trends Analytic Framework-ADHD Market, 2009
Figure 5: Technology Trends Analytic Framework-Description-ADHD Market, 2009
Figure 6: ADHD Therapeutics Market-Clinical Pipeline by Mechanism Of Action, 2009
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.